Conclusion
Although a growing number of specific and surrogate POCTs are now available for SARS-CoV2, test performance is variable across the clinical course. Given existing data, its ease of use and low cost, FebriDx shows promise as a screening tool for early-stage COVID-19 infection in hospital settings. However, not enough is yet known about its value in primary care or community settings. Reliable, SARS CoV2-specific tests – when they become available – are likely to be the preferred option especially during the autumn and winter months when the incidence of other, co-circulating respiratory viral infections will affect the discriminating power of surrogate tests like FebriDx.